Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07116616 · ClinicalTrials.gov registry record · Phase 1

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by ModernaTX.

Recruiting
Registry status
Phase 1
Development phase
166
Enrollment target
10
Study locations

NCT07116616 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 166 participants, below the 326-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (49% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07116616, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, is actively recruiting participants, sponsored by ModernaTX.

RECRUITING
Registry status
Phase 1
Development phase
166 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).

Conditions Studied

Relapsed or Refractory Multiple Myeloma

Interventions

  • DRUG mRNA-2808

Study Locations (10)

New York

  • Tisch Cancer Institute at Mount Sinai - New York
  • Memorial Sloan-Kettering Cancer Center - New York

Alabama

  • University of Alabama at Birmingham Hospital - Birmingham

California

  • UCSF - San Francisco

Georgia

  • Emory University Hospital - Atlanta

Massachusetts

  • Mass General Brigham - Boston

North Carolina

  • Atrium Health Levine Cancer Institute - Charlotte

Pennsylvania

  • Penn Medicine - Philadelphia

Tennessee

  • Sarah Cannon Research Institute - Nashville

Trial Details

FieldValue
Enrollment Target 166 participants
Start Date 2025-09-30
Est. Completion 2032-06-17
Phase Phase 1

Sponsor

ModernaTX

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07116616

The ClinicalTrials.gov registry entry for NCT07116616 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 326-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (49% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which mRNA-2808 is the first listed.

NCT07116616 reports 10 study locations spanning 9 distinct geographic areas - top geographies include New York, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT07116616 about?

NCT07116616 is a clinical study titled "A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).

What is the current status of trial NCT07116616?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2025-09-30. Estimated completion is 2032-06-17.

What conditions does trial NCT07116616 study?

This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.

What interventions are being tested in trial NCT07116616?

The interventions under investigation include: mRNA-2808 (DRUG).

Who is sponsoring clinical trial NCT07116616?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07116616 being conducted?

This trial has 10 study locations across Alabama, California, Georgia, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsed or Refractory Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.